Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
about
ARID1A mutations in endometriosis-associated ovarian carcinomasMolecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and TreatmentARID1A gene silencing reduces the sensitivity of ovarian clear cell carcinoma to cisplatinDifferentiation of epithelial ovarian cancer subtypes by use of imaging and clinical data: a detailed analysis.Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression.Selective cytotoxicity of indirect nonequilibrium atmospheric pressure plasma against ovarian clear-cell carcinoma.A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancerHNF-1β in ovarian carcinomas with serous and clear cell change.Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.Major clinical research advances in gynecologic cancer in 2010Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis.Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.Chemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcome.Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinomaDefective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer.Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.Epigenetic determinants of ovarian clear cell carcinoma biology.Modulation of estrogenic action in clear cell carcinoma of the ovary (Review).Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabineExpression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers.Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma.A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted TherapiesMolecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials.New perspectives on molecular targeted therapy in ovarian clear cell carcinoma.ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary.Upregulation of retinoic acid receptor-β reverses drug resistance in cholangiocarcinoma cells by enhancing susceptibility to apoptosis.Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.The changing 50% inhibitory concentration (IC50) of cisplatin: a pilot study on the artifacts of the MTT assay and the precise measurement of density-dependent chemoresistance in ovarian cancer.Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary.Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.
P2860
Q24610484-CBEA041E-8C94-4D2E-9CA0-DED20B4B14A8Q28066904-D0B51CE4-2067-409B-9E85-5FE6666308C4Q28468340-654814B2-9F5C-47C7-A905-200B449CD1A9Q31044907-91EA1F79-F57E-4871-A6BA-07445DEB3E80Q33355350-1265CD18-A10E-43C7-9A19-7E6544BCCAB3Q33362731-6253BE4D-C548-4D3C-BE5E-D291B1723494Q33462795-669E5461-7E33-44BF-A54F-A150584EB8F2Q33634277-FEF6F21C-B78D-460C-BD69-575DD37C8A15Q33647555-864C9133-3A45-427D-AE06-678298F110F1Q34139923-F781B3AD-137A-4235-ADE6-82C642C19864Q34517694-E7A08CD1-2965-41F4-B702-3F86831FCF0DQ34528724-46D86AB3-C3DD-41EA-B31F-92ABA6301E0CQ34613189-E746A192-7CA8-492A-89D5-59F585B4C13DQ34616645-1EFCB04D-17A8-4828-B623-914DE5AB24D2Q34742974-05090C69-2D65-4B5C-B522-392EFBF4D752Q35020913-C01F7D95-34C3-475A-AEB9-03292954C839Q35057812-52FEEC78-2734-42EA-A89E-DD035E355C81Q35612005-D02946EF-B1C9-4C01-936A-0ED3BB9F2028Q35650181-749F8568-1096-4839-A81E-AC1AABF831CDQ35709343-CE298C36-025E-45BD-AF50-1C849DC9D95AQ35820013-7BBEEA0D-86FC-4F3F-A83B-4665B442048AQ35854002-24629FB7-9615-4C74-B470-A6F8306DFF74Q35908353-51519604-4F09-472A-8C7A-792E96AFC247Q36224720-9AF1539F-CA1C-4BBB-8147-F4A88835FD5FQ36429931-6C227CAB-AC62-4DE6-88B4-7886C5ED6BD5Q36517552-F84B9172-C9D2-4125-97A5-46967CDEA0C5Q36544294-56F6AE3F-4455-4830-91A8-C83873CCD3C1Q36790208-29B974F4-1B54-4659-BD52-797254D179E0Q36826591-7FA8F737-D3B0-440F-B782-183B02A6D28CQ36889642-ED675134-C07E-43EA-8DBE-901C7AC92977Q37225222-5284D53A-514A-42DF-B876-A2802514679EQ37287587-AFB103C0-112B-4257-856B-38EA720E291BQ37297434-D96E5B8D-3795-4DF6-AF57-01EC7701A455Q37316603-65758617-A4F9-440A-9152-7213CA5AE7B9Q37328373-8D35278E-45EB-4376-B002-5C8B9A961D41Q37383301-B8FE5B88-555F-4A3E-9608-C7E687C9B572Q37396993-C5136923-D662-4828-AFAC-74779EA2FA4DQ37688617-D8B50ED9-FE57-4205-9268-61CDDFC04C68Q37776738-1369B9DE-F58F-4AB8-8A2D-89344FD6A590Q38067436-8781EEAE-F4D0-4D29-B0C8-0107B5D376F1
P2860
Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
@en
Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
@nl
type
label
Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
@en
Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
@nl
prefLabel
Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
@en
Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
@nl
P2093
P2860
P1433
P1476
Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
@en
P2093
Hiroaki Itamochi
Junzo Kigawa
Naoki Terakawa
P2860
P304
P356
10.1111/J.1349-7006.2008.00747.X
P577
2008-04-01T00:00:00Z